Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Farnesol Ameliorates Demyelinating Phenotype in a Cellular and Animal Model of Charcot-Marie-Tooth Disease Type 1A.

Current issues in molecular biology - 13 Nov 2021

Park Na-Young, Kwak Geon, Doo Hyun-Myung, Kim Hye-Jin, Jang So-Young, Lee Yun-Il, Choi Byung-Ok, Hong Young-Bin

Abstract excerpt

Charcot-Marie-Tooth disease (CMT) is a genetically heterogeneous disease affecting the peripheral nervous system that is caused by either the demyelination of Schwann cells or degeneration of the peripheral axon. Currently, there are no treatment options to improve the degeneration of peripheral nerves in CMT patients. In this research, we assessed the potency of farnesol for improving the demyelinating phenotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Charcot-Marie-Tooth Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Demyelinating Diseases

Share to Disease Models, Animal

Share to Disease Susceptibility

Share to Gene Expression

Share to Myelin Proteins

Share to Schwann Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 34889893
DOI: 10.3390/cimb43030138
PMCID: PMC8928981

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Farnesol Ameliorates Demyelinating Phenotype in a Cellular and Animal Model of Charcot-Marie-Tooth Disease Type 1A.PMID 34889893Read ↗

Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy.Semantic proximity Read ↗

Charcot-Marie-Tooth: From Molecules to TherapySemantic proximity Read ↗

Mechanisms and Treatments in Demyelinating CMT.Semantic proximity Read ↗

Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease.Semantic proximity Read ↗

Charcot-Marie-Tooth disease: an updateSemantic proximity Read ↗

Navigating the Landscape of CMT1B: Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches.Semantic proximity Read ↗

Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.Semantic proximity Read ↗

Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future PerspectivesSemantic proximity Read ↗

TGFβ4 alleviates the phenotype of Charcot-Marie-Tooth disease type 1A.Semantic proximity Read ↗

Animal models of inherited neuropathiesSemantic proximity Read ↗

Early targeting of endoneurial macrophages alleviates the neuropathy and affects abnormal Schwann cell differentiation in a mouse model of Charcot‐Marie‐Tooth 1ASemantic proximity Read ↗

Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.